MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Cost of Revenue 2011-2026 | BSX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.22 B | 5.26 B | 4.34 B | 3.96 B | 3.71 B | 3.46 B | 3.12 B | 2.81 B | 2.59 B | 2.42 B | 2.17 B | 2.21 B | 2.17 B | 2.35 B | 2.66 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.22 B | 2.17 B | 3.3 B |
Quarterly Cost of Revenue Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.52 B | 1.64 B | 1.45 B | 1.31 B | 1.27 B | 1.21 B | 1.1 B | 1.06 B | 1.04 B | - | 979 M | 1.01 B | 955 M | - | 900 M | 945 M | 894 M | - | 869 M | 791 M | 806 M | - | 777 M | 758 M | 730 M | - | 672 M | 739 M | 672 M | - | 637 M | 632 M | 650 M | - | 594 M | 639 M | 573 M | - | 539 M | 540 M | 520 M | - | 550 M | 563 M | 537 M | - | 510 M | 530 M | 578 M | - | 558 M | 578 M | 631 M | - | 680 M | 688 M | 631 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.64 B | 510 M | 810 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.22 | 5.21 % | $ 3.47 M |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.45 | 0.29 % | $ 1.41 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.36 | -0.24 % | $ 600 M |  Israel |
 |
Alphatec Holdings
ATEC
|
232 M | $ 13.05 | 3.57 % | $ 1.96 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.27 | 9.21 % | $ 904 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.06 | 2.53 % | $ 151 M |  France |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 37.34 | -0.16 % | $ 1.16 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.68 | 4.61 % | $ 37 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.16 | 1.18 % | $ 302 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 65.01 | 2.41 % | $ 1.93 B |  Costa-rica |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.65 | 1.64 % | $ 882 M | Israel |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 110.71 | 0.69 % | $ 193 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.74 | -0.71 % | $ 349 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.6 | 0.39 % | $ 153 M | Israel |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 269.48 | 3.15 % | $ 7.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.17 | -0.91 % | $ 1.32 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 32.75 | -0.27 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 176.12 | 3.94 % | $ 13.2 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.1 | 1.0 % | $ 701 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 33.74 | 2.99 % | $ 5.03 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.74 | 1.91 % | $ 154 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.39 | -6.07 % | $ 40.1 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.33 | - | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 102.8 | 1.09 % | $ 1.31 B | USA |